{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:17:07Z","timestamp":1790929027218,"version":"4.1.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T00:00:00Z","timestamp":1315267200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0001308","type":"journal-article","created":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T20:41:56Z","timestamp":1315341716000},"page":"e1308","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":56,"title":["Melarsoprol Cyclodextrin Inclusion Complexes as Promising Oral Candidates for the Treatment of Human African Trypanosomiasis"],"prefix":"10.1371","volume":"5","author":[{"given":"Jean","family":"Rodgers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Gibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Gettinby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G. E.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,9,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ana.21429","article-title":"The continuing problem of human African trypanosomiasis (sleeping sickness).","volume":"64","author":"PGE Kennedy","year":"2008","journal-title":"Ann Neurol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1172\/JCI200421052","article-title":"Human African trypanosomiasis of the CNS: current issues and challenges.","volume":"113","author":"PGE Kennedy","year":"2004","journal-title":"J Clin Invest"},{"key":"ref3","first-page":"661","article-title":"Clinical manifestations and diagnosis of sleeping sickness.","author":"FIC Apted","year":"1970"},{"key":"ref4","first-page":"321","article-title":"Neurological aspects of human African trypanosomiasis.","author":"JLM Atouguia","year":"2000"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2009.02.007","article-title":"Human African trypanosomiasis, chemotherapy and CNS disease.","volume":"211","author":"J Rodgers","year":"2009","journal-title":"J Neuroimmunol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1017\/S0031182010001137","article-title":"Chemotherapy against human African trypanosomiasis: is there a road to success?","volume":"137","author":"C Burri","year":"2010","journal-title":"Parasitology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0140-6736(00)02141-3","article-title":"Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial.","volume":"355","author":"C Burri","year":"2000","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(09)61163-6","article-title":"NECT trial: more than a small victory over sleeping sickness.","volume":"374","author":"J Opigo","year":"2009","journal-title":"Lancet"},{"key":"ref9","first-page":"1","article-title":"Control and surveillance of African trypanosomiaisis.","volume":"881","year":"1998","journal-title":"WHO technical report series, Geneva"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijpharm.2005.09.003","article-title":"Melarsoprol-cyclodextrins inclusion complexes.","volume":"306","author":"S Gibaud","year":"2005","journal-title":"Int J Pharm"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjp.0707354","article-title":"Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.","volume":"152","author":"MP Barrett","year":"2007","journal-title":"Br J Pharmacol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0035-9203(94)90430-8","article-title":"Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy.","volume":"88","author":"J Pepin","year":"1994","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s002800050998","article-title":"Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia.","volume":"44","author":"SL Soignet","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/path.1700770224","article-title":"The lesions produced in the central nervous system by certain organic arsenical compounds.","volume":"77","author":"EW Hurst","year":"1959","journal-title":"Journal of Pathology and Bacteriology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/0035-9203(80)90183-2","article-title":"Immunopathological and chemotherapeutic studies in experimental trypanosomiaisis with special reference to the heart and brain.","volume":"74","author":"AA Poltera","year":"1980","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0140-6736(92)91531-C","article-title":"Subcurative chemotherapy and fatal post-treatment reactive encephalopathies in African trypanosomiasis.","volume":"339","author":"CA Hunter","year":"1992","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/0035-9203(89)90272-1","article-title":"Trypanosomiasis and encephalitis: possible aetiology and treatment.","volume":"83","author":"FW Jennings","year":"1989","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0035-9203(91)90032-T","article-title":"African trypanosomiasis and drug-induced encephalopathy: risk factors and pathogenesis.","volume":"85","author":"J Pepin","year":"1991","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.trstmh.2007.11.011","article-title":"Diagnosing central nervous system trypanosomiasis: two stage or not to stage?","volume":"102","author":"PGE Kennedy","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1021\/js950534b","article-title":"Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization.","volume":"85","author":"T Loftsson","year":"1996","journal-title":"J Pharm Sci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.044","article-title":"Cyclodextrins and their pharmaceutical applications.","volume":"329","author":"T Loftsson","year":"2007","journal-title":"Int J Pharm"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0001-706X(97)00079-X","article-title":"The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro.","volume":"68","author":"B Raz","year":"1997","journal-title":"Acta Trop"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2307\/3282883","article-title":"Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers.","volume":"75","author":"H Hirumi","year":"1989","journal-title":"J Parasitol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/AAC.38.6.1298","article-title":"Properties of melarsamine hydrochloride (Cymelarsan) in aqueous solution.","volume":"38","author":"BJ Berger","year":"1994","journal-title":"Antimicrob Agents Ch"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/brain\/awg160","article-title":"Clinical and neuroinflammatory responses to meningoencephalitis in substance P receptor knockout mice.","volume":"126","author":"PGE Kennedy","year":"2003","journal-title":"Brain"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4269\/ajtmh.2011.10-0487","article-title":"Magnetic resonance imaging to assess blood-brain barrier damage in murine trypanosomiasis.","volume":"84","author":"J Rodgers","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0169-409X(98)00097-0","article-title":"Delivery of imaging agents into brain.","volume":"37","author":"NJ Abbott","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1073\/pnas.94.8.4167","article-title":"A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei.","volume":"94","author":"PGE Kennedy","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref29","article-title":"Biostatistical analysis","author":"JH Zar","year":"1996"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/QCO.0b013e32833f9fd0","article-title":"Potential new drugs for human African trypanosomiasis: some progress at last.","volume":"23","author":"MP Barrett","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"ref31","article-title":"Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: Pharmacokinetics and tissue distribution in mice.","author":"S Ben Zirar","year":"2008","journal-title":"Eur J Pharm Biopharm"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(98)00052-0","article-title":"Mechanisms of drug release from cyclodextrin complexes.","volume":"36","author":"VJ Stella","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2007.07.018","article-title":"The utility of cyclodextrins for enhancing oral bioavailability.","volume":"123","author":"RL Carrier","year":"2007","journal-title":"J Control Release"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0378-5173(01)00796-7","article-title":"Improved oral bioavailability of artemisinin through inclusion complexation with beta- and gamma-cyclodextrins.","volume":"227","author":"JW Wong","year":"2001","journal-title":"Int J Pharm"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0168-3659(02)00270-5","article-title":"Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-beta-cyclodextrin.","volume":"85","author":"B Evrard","year":"2002","journal-title":"J Control Release"},{"key":"ref36","article-title":"Guidance for Industry.","year":"2005"},{"key":"ref37","year":"2007"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ijpara.2006.01.012","article-title":"Diagnostic and neuropathogenesis issues in human African trypanosomiasis.","volume":"36","author":"PGE Kennedy","year":"2006","journal-title":"Int J Parasitol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1086\/374645","article-title":"Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis.","volume":"187","author":"V Lejon","year":"2003","journal-title":"J Infect Dis"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole\u2013a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness.","volume":"4","author":"E Torreele","year":"2010","journal-title":"PLoS Negl Trop Dis"}],"container-title":["PLoS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0001308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T03:24:55Z","timestamp":1588994695000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0001308"}},"subtitle":[],"editor":[{"given":"Jayne","family":"Raper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,9,6]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0001308","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,6]]}}}